Expert analysis confirms that 88% of psychiatric diagnoses lack FDA-approved medications, establishing rational off-label prescribing and symptom-targeted polypharmacy as essential components of evidence-based clinical practice.
The federal reclassification of state-licensed medical marijuana from Schedule I to Schedule III alters its regulatory status and tax treatment, though it does not constitute full federal legalization.
Psyence Biomedical has initiated a Phase IIb trial for the psilocybin candidate NPX-5 targeting cancer patients, likely addressing cancer-related distress or pain rather than primary psychiatric disorders.
This study identifies baseline patient characteristics in a primary care collaborative care model that predict referral to specialty mental health services for depression and anxiety, offering insights for optimizing treatment pathways.
This case report highlights reversible cerebral vasoconstriction syndrome (RCVS) as a rare but serious adverse event associated with sertraline reinitiation, necessitating heightened clinical vigilance for thunderclap headaches in patients using SSRIs.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Aug 29 – Apr 23)
- Monitor ARIA risk closely in patients on anti-amyloid immunotherapies by adhering to updated Alzheimer's Association guidelines for imaging and symptom mitigation.
- Prescribe clozapine under the new REMS protocols following the conclusion of its previous risk evaluation strategy to ensure regulatory compliance.
- Utilize the xanomeline/trospium combination as a novel muscarinic antagonist option for schizophrenia patients who have not responded to standard antipsychotics.
- Assess prolactin levels with awareness that acute stress can elevate values, and manage hyperprolactinemia by switching to aripiprazole or reducing the offending agent dose.
- Consider combination therapy with specific antipsychotic and mood stabilizer pairs for bipolar disorder patients who have failed lithium monotherapy to reduce relapse risk.
- Evaluate rivastigmine as a potential rescue treatment for hypoactive anticholinergic delirium specifically associated with clozapine toxicity.
- Titrate seizure thresholds carefully during ultrabrief pulse ECT, as this parameter is a critical determinant of clinical efficacy in treatment-resistant depression.
- Incorporate GLP-1 agonists into the management plan for bipolar patients with metabolic syndrome to mitigate cardiovascular risks from mood stabilizers.
- Target TMS therapy based on baseline connectivity to the stimulation site rather than relying solely on induced connectivity changes to predict anxiety improvement.
- Review community pharmacists' insights on antidepressant optimization to identify potential gaps in medication adherence and monitoring for your patient panel.
Policy & Regulation 3
A JAMA study indicates that increased usage of the 988 crisis hotline correlates with an 11% reduction in suicide deaths among adolescents and young adults, suggesting non-pharmacologic crisis intervention is a critical component of suicide prevention.
A commentary argues against accelerating FDA approval for psychedelics like ibogaine based on anecdotal evidence and executive orders, emphasizing the critical need for rigorous randomized controlled trials to address safety risks such as QT prolongation and fatal arrhythmias.
An executive order is accelerating the pace of clinical research into psychedelics for treating severe mental health conditions, potentially expediting future FDA approvals and prescribing pathways.
Drug Development 4
Phase 2 clinical trial results for the investigational antipsychotic LB-102 in schizophrenia have been published in JAMA Psychiatry, providing new evidence on its efficacy and safety profile for potential prescribing.
Neurosterix is advancing the Phase 1 clinical development of NTX-253, a novel investigational agent for schizophrenia, with completion expected in Q2 2026.
A clinical trial is underway to establish the steady-state bioequivalence of a new injectable aripiprazole formulation for schizophrenia, which will inform future prescribing options and generic substitution strategies.
LB Pharmaceuticals released Phase 2 clinical trial data for its investigational agent targeting schizophrenia, providing early efficacy and safety signals relevant to future prescribing strategies.
Diagnosis & Treatment 4
An 8-week mindfulness-based intervention significantly reduces anxiety severity and improves sleep and psychosocial functioning when used as an adjunct to pharmacotherapy in patients with generalized anxiety disorder.
An international study indicates that treating ADHD with psychostimulants in patients with a history of psychosis does not increase the risk of psychotic relapse, supporting their use in this population.
Research indicates that treating ADHD in patients with a history of psychosis does not increase the risk of psychotic relapse, supporting the safety of stimulant or non-stimulant pharmacotherapy in this population.
Clinical Pearl 2
A head-to-head trial indicates that baseline connectivity to the TMS target site predicts anxiety improvement in depression patients, whereas induced connectivity changes did not predict outcomes, suggesting circuit architecture is a critical factor for targeting protocols.
This article provides clinical prescribing guidance for the novel muscarinic antagonist combination xanomeline/trospium, a new treatment option for schizophrenia.
Digital Health 5
A randomized usability trial evaluates a nurse-driven clinical decision support system to improve documentation and assessment of opioid withdrawal severity in Opioid Use Disorder.
This article describes a clinical trial evaluating VR-based relaxation to manage anxiety specifically associated with electroconvulsive therapy (ECT).
This article describes a clinical trial evaluating an AI-based rehabilitation device combined with standard treatment for anxiety disorders, representing a digital health intervention rather than direct pharmacological news.
This article describes a clinical trial evaluating VR-based relaxation to manage anxiety specifically associated with electroconvulsive therapy (ECT).
This article discusses the potential of functional connectivity neurofeedback as a precision treatment modality for psychiatric symptoms, representing an emerging non-pharmacological intervention.
Journal Article 2
A large-scale Swedish and Finnish cohort study identifies specific antipsychotic and mood stabilizer combinations that significantly reduce relapse risk compared to lithium monotherapy in bipolar disorder patients, offering evidence-based alternatives for those with inadequate response or intolerance.
This article is an obituary for William H. Morse, a founding figure in behavioral pharmacology whose work on drug effects on operant behavior laid the groundwork for modern psychiatric psychopharmacology.
Mechanism of Action 5
This review reframes contemporary psychosurgery as circuit-based medicine using connectomics to guide neuromodulation and ablation for treatment-resistant psychiatric conditions, emphasizing integration with pharmacological strategies.
A novel discovery linking Tourette's tics to an emotion-linked brain circuit suggests potential new therapeutic targets beyond traditional motor-focused approaches.
This study identifies IL-15 receptor alpha deficiency as a mechanism for depressive-like behaviors through enhanced microglial synapse pruning, offering a novel target for future pharmacological intervention.
Preclinical PET imaging demonstrates that subanesthetic ketamine rapidly increases cAMP activity via PDE4 inhibition in rodents and non-human primates, providing mechanistic evidence for its rapid antidepressant effects.
This preclinical study indicates that NMDA receptor antagonism requires intact serotonin and noradrenaline signaling to produce antidepressant effects, suggesting potential limitations for ketamine-based therapies in patients with severe monoaminergic deficits.
Neuroscience 2
Identification of a shared neural pathway between the motor and insular cortex in Tourette's and OCD provides mechanistic insight for future pharmacological targeting but does not currently alter prescribing practices.
This review proposes a framework linking neuroinflammation and immune dysregulation to computational deficits in schizophrenia, advocating for multi-modal biomarkers to enable precision medicine rather than offering specific new drug prescribing guidance.
Substance Use 5
A large-scale survey estimates that 2.8% of the U.S. population used psilocybin in the past year, providing critical epidemiological data for clinicians monitoring emerging psychedelic use patterns.
A new survey indicates 2.8% of US adults used psilocybin in the past year, driven by decriminalization efforts and growing interest in its potential antidepressant effects.
This systematic review identifies single-item patient-reported outcome measures for substance use treatment that offer valid, reliable alternatives to lengthy assessments for monitoring craving, treatment readiness, and self-efficacy.
This national analysis indicates that state-level kratom bans correlate with significantly lower rates of severe medical outcomes and healthcare utilization compared to unrestricted states, informing regulatory strategies for substance use disorders.
This editorial highlights the urgent need for integrated treatment frameworks addressing stimulant use disorder and co-occurring psychiatric conditions like ADHD, while noting emerging pharmacotherapies such as a cocaine vaccine and gaps in current evidence-based interventions.